Millennium Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (1993)
Status: Acquired by Takeda (2008)

Organization Overview

First Clinical Trial
2000
NCT00655135
First Marketed Drug
2001
alemtuzumab (campath)
First NDA Approval
2001
alemtuzumab (campath)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Millenium Pharmaceuticals | Millennium Pharmaceuticals, Inc. | MILLENNIUM PHARMS